The Capital Partnership

The Capital Partnership is an independent asset manager providing institutional and private investors with a comprehensive range of asset management and wealth preservation services. Established in 1998, The Capital Partnership was created to provide sophisticated investment services to the families of its founding partners. The success of the firm's approach allowed it to expand its services and capabilities and offer them to institutions and other large families in EMEA with similar asset management requirements. With offices in London and Dubai, The Capital Partnership is the advisor to a number of leading global institutions and family groups - helping them to address a range of challenges to the growth and preservation of their assets. The Capital Partnership Group Limited, the group's ultimate holding company is incorporated in the Dubai International Financial Centre (DIFC). The Capital Partnership (UK) Limited, the group's UK operating subsidiary is Authorised and Regulated by the Financial Conduct Authority.

Ahmed Ben Halim

Founding Partner

Gautam Kainth

Managing Director

McNeill, Chris

Senior Investment Analyst

28 past transactions

Supira Medical

Series E in 2025
Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Laza Medical

Series A in 2023
Laza Medical is a privately held startup that specializes in the development of AI-powered robotic imaging solutions for cardiovascular treatments. The company aims to enhance the quality of imaging in cardiac interventions by integrating advanced artificial intelligence software with robotic technology. This innovative approach is designed to optimize procedural workflows and improve the standard of imaging for cardiovascular procedures. By providing a user-friendly interface, Laza Medical seeks to make high-quality imaging and advanced procedural navigation accessible to a wide range of clinicians, ultimately enhancing patient care in the field of cardiovascular medicine.

Supira Medical

Series D in 2023
Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Akura Medical

Series B in 2023
Akura Medical is focused on developing innovative medical devices aimed at improving the process of thrombectomy, specifically through a next-generation device designed for easy use in a single-pass procedure to efficiently remove blood clots. The company specializes in thrombectomy devices and also offers a range of surgical, medical, dental, and veterinary instruments. By providing effective solutions for clot removal, Akura Medical enables healthcare professionals to better address critical needs and treat venous thromboembolism of varying sizes.

Myra Vision

Series B in 2023
Myra Vision is engaged in developing innovative treatment solutions for patients suffering from moderate to severe glaucoma. The company focuses on surgical techniques that effectively reduce intraocular pressure (IOP), addressing significant gaps in existing therapies. By providing a platform that minimizes the risk of hypotony, Myra Vision aims to enhance treatment options for physicians and improve patient outcomes in managing glaucoma.

Tioga Cardiovascular

Series C in 2023
Tioga Cardiovascular is a privately held company under Shifamed LLC, specializing in the development of medical devices for valve replacement in mitral and tricuspid applications. The company is dedicated to creating innovative solutions that simplify procedures and utilize less invasive, transcatheter techniques. By focusing on elegant design and functionality, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, providing healthcare professionals with advanced tools for treating patients with valvular heart diseases.

Atia Vision

Series E in 2022
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative solutions for eye care. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses that address the needs of the intraocular lens replacement market. Atia Vision's technology mimics the natural accommodation of the eye by utilizing the ciliary muscles, which allows for a full range of functional vision restoration for cataract patients. The accommodating intraocular lenses are designed to provide effective vision correction without the need for glasses, thereby improving patient outcomes and enhancing the overall quality of life for individuals with vision impairment.

Adona Medical

Series B in 2022
Adona Medical is a privately held company focused on developing innovative interventional solutions for heart failure, a condition that affects around 6.5 million patients in the United States and approximately 26 million worldwide. The company's heart failure management system is designed for personalized care, utilizing advanced sensor and shunt technologies to enhance the standard of heart care. By implementing interatrial shunt technology, Adona Medical aims to improve the understanding of a patient's hemodynamic status, allowing healthcare providers to tailor treatments to individual needs and ultimately enhance patient outcomes in managing heart failure.

Supira Medical

Series C in 2022
Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Mindstep

Seed Round in 2022
Mindstep is a developer of cognitive and mental health digital therapeutics aimed at reducing the risk of dementia. Founded by medical professionals, the company prioritizes accessibility, empathy, and scientific rigor in delivering effective care. Its innovative platform leverages machine learning and clinical research to create digital solutions that allow users to conduct self-screenings for dementia, thereby overcoming limitations in traditional healthcare access. By providing a virtual clinic experience, Mindstep seeks to empower individuals with tools for better mental health management and improved cognitive outcomes.

Akura Medical

Series A in 2022
Akura Medical is focused on developing innovative medical devices aimed at improving the process of thrombectomy, specifically through a next-generation device designed for easy use in a single-pass procedure to efficiently remove blood clots. The company specializes in thrombectomy devices and also offers a range of surgical, medical, dental, and veterinary instruments. By providing effective solutions for clot removal, Akura Medical enables healthcare professionals to better address critical needs and treat venous thromboembolism of varying sizes.

Elemy

Series B in 2021
Elemy is a nationwide provider of childhood behavioral and mental healthcare, specializing in areas such as autism, ADHD, OCD, depression, social anxiety, and bipolar disorder. Launched in April 2020, the company utilizes a technology-driven care model that modernizes traditional healthcare delivery through in-home services. This approach enhances access to care, improves clinical outcomes, and reduces costs. Elemy's platform offers free autism assessments and matches children with therapists to develop individualized treatment plans tailored to their specific needs. The multidisciplinary clinical team implements an integrated treatment model that has demonstrated significant improvements in behavior. Backed by notable venture capital and healthcare investors, Elemy is committed to transforming the landscape of childhood mental health care.

Tioga Cardiovascular

Series B in 2021
Tioga Cardiovascular is a privately held company under Shifamed LLC, specializing in the development of medical devices for valve replacement in mitral and tricuspid applications. The company is dedicated to creating innovative solutions that simplify procedures and utilize less invasive, transcatheter techniques. By focusing on elegant design and functionality, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, providing healthcare professionals with advanced tools for treating patients with valvular heart diseases.

Myra Vision

Series A in 2021
Myra Vision is engaged in developing innovative treatment solutions for patients suffering from moderate to severe glaucoma. The company focuses on surgical techniques that effectively reduce intraocular pressure (IOP), addressing significant gaps in existing therapies. By providing a platform that minimizes the risk of hypotony, Myra Vision aims to enhance treatment options for physicians and improve patient outcomes in managing glaucoma.

Myra Vision

Series A in 2021
Myra Vision is engaged in developing innovative treatment solutions for patients suffering from moderate to severe glaucoma. The company focuses on surgical techniques that effectively reduce intraocular pressure (IOP), addressing significant gaps in existing therapies. By providing a platform that minimizes the risk of hypotony, Myra Vision aims to enhance treatment options for physicians and improve patient outcomes in managing glaucoma.

Collective Health

Series F in 2021
Collective Health is a prominent health benefits platform that streamlines the management of medical, dental, vision, and pharmacy services for employees and their families. By offering an integrated solution through a cloud-based self-insurance platform, the company simplifies the administration of health plans via a single portal. This platform provides users with clear guidance, live concierge support, and digital tools to facilitate the navigation and management of healthcare services. Collective Health aims to reduce the complexities of delivering health benefits, enhance the member experience, and promote healthier outcomes for both employees and organizations. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.

Supira Medical

Series B in 2020
Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

CloudCath

Series A in 2020
CloudCath is offering a sensor enabled digital platform for peritoneal dialysis patients that provides early complication detection and safely reduces the number of monthly patient visits.

Palantir Technologies

Venture Round in 2019
Palantir Technologies develops data fusion platforms tailored for public institutions, commercial enterprises, and non-profit organizations globally. Its primary offerings include Palantir Gotham, which integrates, manages, secures, and analyzes enterprise data, and Palantir Foundry, designed for commercial applications that enhance collaboration and data analysis. The company's software aids various sectors, including government, defense, finance, and healthcare, in navigating large and complex data sets to improve operational efficiency and decision-making. Palantir's solutions address a range of critical areas such as anti-fraud, crisis response, cyber security, and healthcare delivery. Founded in 2003 and headquartered in Palo Alto, California, the company maintains strategic partnerships to enhance its service offerings.

Atia Vision

Series D in 2019
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative solutions for eye care. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses that address the needs of the intraocular lens replacement market. Atia Vision's technology mimics the natural accommodation of the eye by utilizing the ciliary muscles, which allows for a full range of functional vision restoration for cataract patients. The accommodating intraocular lenses are designed to provide effective vision correction without the need for glasses, thereby improving patient outcomes and enhancing the overall quality of life for individuals with vision impairment.

Tioga Cardiovascular

Series A in 2019
Tioga Cardiovascular is a privately held company under Shifamed LLC, specializing in the development of medical devices for valve replacement in mitral and tricuspid applications. The company is dedicated to creating innovative solutions that simplify procedures and utilize less invasive, transcatheter techniques. By focusing on elegant design and functionality, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, providing healthcare professionals with advanced tools for treating patients with valvular heart diseases.

NuVera Medical

Seed Round in 2019
NuVera Medical, Inc. is a privately held company based in Campbell, California, specializing in the development of an innovative imaging platform designed for complex cardiovascular procedures. Established in 2016, the company utilizes advanced 4D ultrasound technology to enhance intracardiac echocardiography. This platform enables healthcare specialists, particularly cardiologists, to perform transcatheter cardiac interventions by providing real-time visualization of heart chambers. This capability supports informed decision-making during procedures, ultimately aiming to improve patient outcomes in cardiovascular care. NuVera Medical operates under the portfolio of Shifamed, LLC.

Atia Vision

Series C in 2018
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative solutions for eye care. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses that address the needs of the intraocular lens replacement market. Atia Vision's technology mimics the natural accommodation of the eye by utilizing the ciliary muscles, which allows for a full range of functional vision restoration for cataract patients. The accommodating intraocular lenses are designed to provide effective vision correction without the need for glasses, thereby improving patient outcomes and enhancing the overall quality of life for individuals with vision impairment.

Supira Medical

Series A in 2018
Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

NuVera Medical

Series A in 2017
NuVera Medical, Inc. is a privately held company based in Campbell, California, specializing in the development of an innovative imaging platform designed for complex cardiovascular procedures. Established in 2016, the company utilizes advanced 4D ultrasound technology to enhance intracardiac echocardiography. This platform enables healthcare specialists, particularly cardiologists, to perform transcatheter cardiac interventions by providing real-time visualization of heart chambers. This capability supports informed decision-making during procedures, ultimately aiming to improve patient outcomes in cardiovascular care. NuVera Medical operates under the portfolio of Shifamed, LLC.

Cerestra

Acquisition in 2016
Cerestra is a private equity firm that specializes in investing in real estate assets that are socially relevant and critical for business. The firm focuses on sectors such as K-12 education infrastructure, student housing, life sciences real estate, and industrial light manufacturing facilities. By providing a platform for innovative and risk-mitigated investment opportunities, Cerestra aims to create a unique investment landscape that fosters strong relationships and proprietary strategies. Through its targeted approach, the firm seeks to address essential needs within these sectors while delivering value to its investors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.